AveXis, a Novartis company, announced a one-time infusion of Zolgensma (onasemnogene abeparvovec-xioi) showed rapid, significant and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across… read more.
Pfizer Inc announced that the FDA has approved its supplemental New Drug Application (sNDA) for Eucrisa (crisaborole) ointment, 2%, extending the lower age limit from 24 months down… read more.
Takeda Pharmaceutical Company Limited announced that The Lancet published two papers related to Takeda’s dengue vaccine candidate (TAK 003), reporting on results from the 18-month analysis of the… read more.
Merck Inc., announced top-line efficacy results from two ongoing pivotal Phase III trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK 7264) , an investigational,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
